阿斯利康,石药 z-bio 2025-07-03 2437

　　Today (June 13), AstraZeneca and Shijiao Group reached a strategic cooperation. The two parties will focus on high-priority targets and cooperate to promote the discovery and development of new oral candidates.

　　Shiyao Group will use its AI engine dual-wheel drive high-efficiency drug discovery platform to conduct research. The platform uses AI technology to analyze the binding mode of targeted proteins and existing compound molecules and performs targeted optimization, aiming to screen out small molecules with efficient and excellent development potential.

　　Under the agreement, Shijiao Group will receive a prepayment of US$110 million and qualify for a potential R&D milestone payment of up to US$1.62 billion and a potential sales milestone payment of up to US$3.6 billion, as well as a potential single-digit sales commission based on annual net sales of the product.

　　As a global pharmaceutical giant, AstraZeneca continues to make efforts in the pharmaceutical market with its profound experience in drug research and development, clinical trials and marketing promotion. As a large Chinese pharmaceutical company, Shijiao Group has also shown outstanding strength in drug research and development, especially in the emerging field of AI-driven small molecule drug design platform, which has made remarkable progress.

　　This cooperation is of great significance and injects new vitality into the pharmaceutical industry in multiple dimensions.

　　For drug research and development, the two sides have complementary advantages. The combination of AstraZeneca's profound industry heritage and the cutting-edge AI technology of Shijiao Group is expected to accelerate the research and development process of new oral candidates, bringing new treatment options faster for patients with a variety of chronic diseases.

　　From the perspective of R&D efficiency, the deep integration of AI technology can accurately analyze massive data and accurately screen drug molecules, greatly improving the efficiency and accuracy of drug discovery, thereby effectively reducing R&D costs and time.

　　In terms of market expansion, AstraZeneca has used this cooperation to further enrich its product pipeline and enhance its competitiveness in the Chinese and global markets; Shijiao Group has taken this opportunity to show its innovative strength to the international market and further enhance its popularity and influence in the international pharmaceutical market.

　　More importantly, this strategic cooperation provides a valuable example for the in-depth cooperation between industry, academia and research in the pharmaceutical industry, effectively promotes the deep integration of AI technology and drug research and development, leads the entire pharmaceutical industry to move towards intelligent and efficient innovative development, and contributes key strength to the upgrading and development of the global pharmaceutical industry.